Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus

Liver fibrosis remains an important risk factor for hepatocarcinogenesis in patients with chronic hepatitis C even after the eradication of hepatitis C virus (HCV). However, it is difficult to estimate liver fibrosis based on liver biopsy after the eradication of HCV. We investigated the ability of...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-07, Vol.10 (7), p.e0133515-e0133515
Main Authors: Tachi, Yoshihiko, Hirai, Takanori, Toyoda, Hidenori, Tada, Toshifumi, Hayashi, Kazuhiko, Honda, Takashi, Ishigami, Masatoshi, Goto, Hidemi, Kumada, Takashi
Format: Article
Language:English
Subjects:
Accuracy
Aged
Antiviral agents
Antiviral drugs
Aspartate
Aspartate aminotransferase
Bile
Biological products industry
Biopsy
Blood platelets
Care and treatment
Female
Fibrosis
Follow-Up Studies
Gastroenterology
Hepacivirus
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - pathology
Hepatology
Hospitals
Humans
Infections
Interferon
Laboratories
Liver
Liver cancer
Liver Cirrhosis - blood
Liver Cirrhosis - etiology
Liver Cirrhosis - pathology
Liver diseases
Male
Medicine
Middle Aged
Patients
Quality
Risk factors
Transaminase
University graduates
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3
cites cdi_FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3
container_end_page e0133515
container_issue 7
container_start_page e0133515
container_title PloS one
container_volume 10
creator Tachi, Yoshihiko
Hirai, Takanori
Toyoda, Hidenori
Tada, Toshifumi
Hayashi, Kazuhiko
Honda, Takashi
Ishigami, Masatoshi
Goto, Hidemi
Kumada, Takashi
description Liver fibrosis remains an important risk factor for hepatocarcinogenesis in patients with chronic hepatitis C even after the eradication of hepatitis C virus (HCV). However, it is difficult to estimate liver fibrosis based on liver biopsy after the eradication of HCV. We investigated the ability of laboratory indices to predict liver fibrosis in patients with sustained virologic response (SVR) to antiviral therapy. Three laboratory liver fibrosis indices (aspartate aminotransferase-platelet ratio index (APRI), FIB-4 index, and Forns index) were calculated based on data at the time of initial pretreatment liver biopsy and at second liver biopsy performed approximately 5 years after SVR in 115 patients who underwent serial liver biopsies. The indices at the time of initial biopsy were compared to histological degree of liver fibrosis in initial biopsy, and laboratory indices at the time of second liver biopsy were compared to the degree of fibrosis in second biopsy. In both comparisons, there were significant increases in all 3 indices with the increase of liver fibrosis grade as assessed in liver biopsy specimens. All 3 indices at the time of second biopsy were able to predict moderate to advanced (METAVIR score F2-4) and advanced (F3-4) fibrosis on liver biopsy, with the area under the receiver-operating characteristics curve >0.8 and the accuracy >70%. All 3 laboratory indices of fibrosis accurately reflected liver fibrosis in patients with SVR for 5 years despite the normalization of serum liver transaminase activity and the lack of liver inflammation.
doi_str_mv 10.1371/journal.pone.0133515
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1699200853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A423309671</galeid><doaj_id>oai_doaj_org_article_98b69298770a40678ae8e9a331091060</doaj_id><sourcerecordid>A423309671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3</originalsourceid><addsrcrecordid>eNqNk99u0zAUxiMEYmPwBggsISG4aLHjxE5ukKpqY5UqbeLPbi3HsRtXadzZzqDPwEtzSrOpQbtAuUh0zu_7jn1yTpK8JnhKKCef1q73nWynW9fpKSaU5iR_kpySkqYTlmL69Oj7JHkRwhrjnBaMPU9OUpaSjBT4NPl97XVtVbR3Gs0q29q4Q86gpaycl9H5HVp0kNcBGefREjCPLmzlXbAB2Q5dy2h1FwP6aWOD5o13nVXoUm8hHgGZI2kiaGKj0bmXYAUJ1-1rHEM31vfhZfLMyDboV8P7LPlxcf59fjlZXn1ZzGfLiWJlGicyLRXmmKSGV7SoTYYN5ZwaXus0z4iRqs60IoSXypispjWXOE_zumCc1ZxLepa8PfhuWxfE0McgCCvLFOMip0AsDkTt5Fpsvd1IvxNOWvE34PxKSB-tarUoiwpOVRacY5lhxgupC11KSgkuCWYYvD4P1fpqo2sF3fKyHZmOM51txMrdiSwnjBIOBh8GA-9uex2i2NigdNvKTrsezs0xJjhneQbou3_Qx283UCsJF7CdcVBX7U3FLEspxSXjBKjpIxQ8td5YBUNnLMRHgo8jATBR_4or2YcgFt--_j97dTNm3x-xjZZtbIJr-_0chTGYHUAF4xm8Ng9NJljsd-a-G2K_M2LYGZC9Of5BD6L7JaF_AC5eENg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1699200853</pqid></control><display><type>article</type><title>Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Tachi, Yoshihiko ; Hirai, Takanori ; Toyoda, Hidenori ; Tada, Toshifumi ; Hayashi, Kazuhiko ; Honda, Takashi ; Ishigami, Masatoshi ; Goto, Hidemi ; Kumada, Takashi</creator><contributor>Yu, Ming-Lung</contributor><creatorcontrib>Tachi, Yoshihiko ; Hirai, Takanori ; Toyoda, Hidenori ; Tada, Toshifumi ; Hayashi, Kazuhiko ; Honda, Takashi ; Ishigami, Masatoshi ; Goto, Hidemi ; Kumada, Takashi ; Yu, Ming-Lung</creatorcontrib><description>Liver fibrosis remains an important risk factor for hepatocarcinogenesis in patients with chronic hepatitis C even after the eradication of hepatitis C virus (HCV). However, it is difficult to estimate liver fibrosis based on liver biopsy after the eradication of HCV. We investigated the ability of laboratory indices to predict liver fibrosis in patients with sustained virologic response (SVR) to antiviral therapy. Three laboratory liver fibrosis indices (aspartate aminotransferase-platelet ratio index (APRI), FIB-4 index, and Forns index) were calculated based on data at the time of initial pretreatment liver biopsy and at second liver biopsy performed approximately 5 years after SVR in 115 patients who underwent serial liver biopsies. The indices at the time of initial biopsy were compared to histological degree of liver fibrosis in initial biopsy, and laboratory indices at the time of second liver biopsy were compared to the degree of fibrosis in second biopsy. In both comparisons, there were significant increases in all 3 indices with the increase of liver fibrosis grade as assessed in liver biopsy specimens. All 3 indices at the time of second biopsy were able to predict moderate to advanced (METAVIR score F2-4) and advanced (F3-4) fibrosis on liver biopsy, with the area under the receiver-operating characteristics curve &gt;0.8 and the accuracy &gt;70%. All 3 laboratory indices of fibrosis accurately reflected liver fibrosis in patients with SVR for 5 years despite the normalization of serum liver transaminase activity and the lack of liver inflammation.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0133515</identifier><identifier>PMID: 26214180</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Accuracy ; Aged ; Antiviral agents ; Antiviral drugs ; Aspartate ; Aspartate aminotransferase ; Bile ; Biological products industry ; Biopsy ; Blood platelets ; Care and treatment ; Female ; Fibrosis ; Follow-Up Studies ; Gastroenterology ; Hepacivirus ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - pathology ; Hepatology ; Hospitals ; Humans ; Infections ; Interferon ; Laboratories ; Liver ; Liver cancer ; Liver Cirrhosis - blood ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; Liver diseases ; Male ; Medicine ; Middle Aged ; Patients ; Quality ; Risk factors ; Transaminase ; University graduates ; Viruses</subject><ispartof>PloS one, 2015-07, Vol.10 (7), p.e0133515-e0133515</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Tachi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Tachi et al 2015 Tachi et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3</citedby><cites>FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1699200853/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1699200853?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26214180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Yu, Ming-Lung</contributor><creatorcontrib>Tachi, Yoshihiko</creatorcontrib><creatorcontrib>Hirai, Takanori</creatorcontrib><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Tada, Toshifumi</creatorcontrib><creatorcontrib>Hayashi, Kazuhiko</creatorcontrib><creatorcontrib>Honda, Takashi</creatorcontrib><creatorcontrib>Ishigami, Masatoshi</creatorcontrib><creatorcontrib>Goto, Hidemi</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><title>Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Liver fibrosis remains an important risk factor for hepatocarcinogenesis in patients with chronic hepatitis C even after the eradication of hepatitis C virus (HCV). However, it is difficult to estimate liver fibrosis based on liver biopsy after the eradication of HCV. We investigated the ability of laboratory indices to predict liver fibrosis in patients with sustained virologic response (SVR) to antiviral therapy. Three laboratory liver fibrosis indices (aspartate aminotransferase-platelet ratio index (APRI), FIB-4 index, and Forns index) were calculated based on data at the time of initial pretreatment liver biopsy and at second liver biopsy performed approximately 5 years after SVR in 115 patients who underwent serial liver biopsies. The indices at the time of initial biopsy were compared to histological degree of liver fibrosis in initial biopsy, and laboratory indices at the time of second liver biopsy were compared to the degree of fibrosis in second biopsy. In both comparisons, there were significant increases in all 3 indices with the increase of liver fibrosis grade as assessed in liver biopsy specimens. All 3 indices at the time of second biopsy were able to predict moderate to advanced (METAVIR score F2-4) and advanced (F3-4) fibrosis on liver biopsy, with the area under the receiver-operating characteristics curve &gt;0.8 and the accuracy &gt;70%. All 3 laboratory indices of fibrosis accurately reflected liver fibrosis in patients with SVR for 5 years despite the normalization of serum liver transaminase activity and the lack of liver inflammation.</description><subject>Accuracy</subject><subject>Aged</subject><subject>Antiviral agents</subject><subject>Antiviral drugs</subject><subject>Aspartate</subject><subject>Aspartate aminotransferase</subject><subject>Bile</subject><subject>Biological products industry</subject><subject>Biopsy</subject><subject>Blood platelets</subject><subject>Care and treatment</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology</subject><subject>Hepacivirus</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - pathology</subject><subject>Hepatology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infections</subject><subject>Interferon</subject><subject>Laboratories</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Quality</subject><subject>Risk factors</subject><subject>Transaminase</subject><subject>University graduates</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk99u0zAUxiMEYmPwBggsISG4aLHjxE5ukKpqY5UqbeLPbi3HsRtXadzZzqDPwEtzSrOpQbtAuUh0zu_7jn1yTpK8JnhKKCef1q73nWynW9fpKSaU5iR_kpySkqYTlmL69Oj7JHkRwhrjnBaMPU9OUpaSjBT4NPl97XVtVbR3Gs0q29q4Q86gpaycl9H5HVp0kNcBGefREjCPLmzlXbAB2Q5dy2h1FwP6aWOD5o13nVXoUm8hHgGZI2kiaGKj0bmXYAUJ1-1rHEM31vfhZfLMyDboV8P7LPlxcf59fjlZXn1ZzGfLiWJlGicyLRXmmKSGV7SoTYYN5ZwaXus0z4iRqs60IoSXypispjWXOE_zumCc1ZxLepa8PfhuWxfE0McgCCvLFOMip0AsDkTt5Fpsvd1IvxNOWvE34PxKSB-tarUoiwpOVRacY5lhxgupC11KSgkuCWYYvD4P1fpqo2sF3fKyHZmOM51txMrdiSwnjBIOBh8GA-9uex2i2NigdNvKTrsezs0xJjhneQbou3_Qx283UCsJF7CdcVBX7U3FLEspxSXjBKjpIxQ8td5YBUNnLMRHgo8jATBR_4or2YcgFt--_j97dTNm3x-xjZZtbIJr-_0chTGYHUAF4xm8Ng9NJljsd-a-G2K_M2LYGZC9Of5BD6L7JaF_AC5eENg</recordid><startdate>20150727</startdate><enddate>20150727</enddate><creator>Tachi, Yoshihiko</creator><creator>Hirai, Takanori</creator><creator>Toyoda, Hidenori</creator><creator>Tada, Toshifumi</creator><creator>Hayashi, Kazuhiko</creator><creator>Honda, Takashi</creator><creator>Ishigami, Masatoshi</creator><creator>Goto, Hidemi</creator><creator>Kumada, Takashi</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150727</creationdate><title>Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus</title><author>Tachi, Yoshihiko ; Hirai, Takanori ; Toyoda, Hidenori ; Tada, Toshifumi ; Hayashi, Kazuhiko ; Honda, Takashi ; Ishigami, Masatoshi ; Goto, Hidemi ; Kumada, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Accuracy</topic><topic>Aged</topic><topic>Antiviral agents</topic><topic>Antiviral drugs</topic><topic>Aspartate</topic><topic>Aspartate aminotransferase</topic><topic>Bile</topic><topic>Biological products industry</topic><topic>Biopsy</topic><topic>Blood platelets</topic><topic>Care and treatment</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology</topic><topic>Hepacivirus</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - pathology</topic><topic>Hepatology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infections</topic><topic>Interferon</topic><topic>Laboratories</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Quality</topic><topic>Risk factors</topic><topic>Transaminase</topic><topic>University graduates</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tachi, Yoshihiko</creatorcontrib><creatorcontrib>Hirai, Takanori</creatorcontrib><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Tada, Toshifumi</creatorcontrib><creatorcontrib>Hayashi, Kazuhiko</creatorcontrib><creatorcontrib>Honda, Takashi</creatorcontrib><creatorcontrib>Ishigami, Masatoshi</creatorcontrib><creatorcontrib>Goto, Hidemi</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tachi, Yoshihiko</au><au>Hirai, Takanori</au><au>Toyoda, Hidenori</au><au>Tada, Toshifumi</au><au>Hayashi, Kazuhiko</au><au>Honda, Takashi</au><au>Ishigami, Masatoshi</au><au>Goto, Hidemi</au><au>Kumada, Takashi</au><au>Yu, Ming-Lung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-07-27</date><risdate>2015</risdate><volume>10</volume><issue>7</issue><spage>e0133515</spage><epage>e0133515</epage><pages>e0133515-e0133515</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Liver fibrosis remains an important risk factor for hepatocarcinogenesis in patients with chronic hepatitis C even after the eradication of hepatitis C virus (HCV). However, it is difficult to estimate liver fibrosis based on liver biopsy after the eradication of HCV. We investigated the ability of laboratory indices to predict liver fibrosis in patients with sustained virologic response (SVR) to antiviral therapy. Three laboratory liver fibrosis indices (aspartate aminotransferase-platelet ratio index (APRI), FIB-4 index, and Forns index) were calculated based on data at the time of initial pretreatment liver biopsy and at second liver biopsy performed approximately 5 years after SVR in 115 patients who underwent serial liver biopsies. The indices at the time of initial biopsy were compared to histological degree of liver fibrosis in initial biopsy, and laboratory indices at the time of second liver biopsy were compared to the degree of fibrosis in second biopsy. In both comparisons, there were significant increases in all 3 indices with the increase of liver fibrosis grade as assessed in liver biopsy specimens. All 3 indices at the time of second biopsy were able to predict moderate to advanced (METAVIR score F2-4) and advanced (F3-4) fibrosis on liver biopsy, with the area under the receiver-operating characteristics curve &gt;0.8 and the accuracy &gt;70%. All 3 laboratory indices of fibrosis accurately reflected liver fibrosis in patients with SVR for 5 years despite the normalization of serum liver transaminase activity and the lack of liver inflammation.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26214180</pmid><doi>10.1371/journal.pone.0133515</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2015-07, Vol.10 (7), p.e0133515-e0133515
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1699200853
source Publicly Available Content Database; PubMed Central
subjects Accuracy
Aged
Antiviral agents
Antiviral drugs
Aspartate
Aspartate aminotransferase
Bile
Biological products industry
Biopsy
Blood platelets
Care and treatment
Female
Fibrosis
Follow-Up Studies
Gastroenterology
Hepacivirus
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - pathology
Hepatology
Hospitals
Humans
Infections
Interferon
Laboratories
Liver
Liver cancer
Liver Cirrhosis - blood
Liver Cirrhosis - etiology
Liver Cirrhosis - pathology
Liver diseases
Male
Medicine
Middle Aged
Patients
Quality
Risk factors
Transaminase
University graduates
Viruses
title Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20Ability%20of%20Laboratory%20Indices%20for%20Liver%20Fibrosis%20in%20Patients%20with%20Chronic%20Hepatitis%20C%20after%20the%20Eradication%20of%20Hepatitis%20C%20Virus&rft.jtitle=PloS%20one&rft.au=Tachi,%20Yoshihiko&rft.date=2015-07-27&rft.volume=10&rft.issue=7&rft.spage=e0133515&rft.epage=e0133515&rft.pages=e0133515-e0133515&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0133515&rft_dat=%3Cgale_plos_%3EA423309671%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-a29c07012f7b38df40f3773f7de2541facd4ec1179cff4d3d7a0525d8676d77a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1699200853&rft_id=info:pmid/26214180&rft_galeid=A423309671&rfr_iscdi=true